Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 22:24 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Effectiveness and Safety of Two Approaches to the Management of Type 2 Diabetes Mellitus in Australian Primary Care
NCT00950534 · Sanofi · PHASE4 · terminated · last registry update 2011-11-10 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “due to poor recruitment” | – | Registry record, Sanofi |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against INSR within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2012-10-24Phase 3 first posted: Novo Nordisk A/S, insulin degludec/insulin aspart + insulin degludec (NCT01713530)
- 2012-10-12Results posted on the registry: Emory University, Sorafenib and OSI-906 (NCT01334710)
- 2012-09-07Phase 3 first posted: Medical University of Vienna, Insulin lispro, Humalog (Eli Lilly) in insulin pump + Human insulin isophane, Humulin N (Eli Lilly) (NCT01680185)
- 2012-09-07Phase 3 first posted: Novo Nordisk A/S, insulin degludec/insulin aspart + insulin degludec/insulin aspart (NCT01680341)
- 2012-08-30Phase 3 first posted: Novo Nordisk A/S, insulin degludec/liraglutide + liraglutide (NCT01676116)
- 2012-08-14Phase 3 first posted: Novo Nordisk A/S, insulin degludec + placebo (NCT01664247)
- 2012-06-13Phase 3 first posted: Novo Nordisk A/S, insulin degludec/liraglutide + placebo (NCT01618162)
- 2012-06-12Phase 3 first posted: Sheffield Teaching Hospitals NHS Foundation Trust, a drug against INSR (NCT01616784)
- 2012-04-20Phase 3 first posted: Eli Lilly and Company, LY2605541 + Insulin glargine (NCT01582451)
- 2012-04-04Phase 3 first posted: Novo Nordisk A/S, insulin degludec + insulin glargine (NCT01570751)
- 2012-03-26Phase 3 first posted: Novo Nordisk A/S, repaglinide + insulin NPH (NCT01562561)
- 2012-01-20Phase 3 first posted: Novo Nordisk A/S, insulin degludec + insulin detemir (NCT01513473)
- 2012-01-20Phase 3 first posted: Novo Nordisk A/S, insulin degludec/insulin aspart (NCT01513590)
- 2011-12-05Results posted on the registry: Novo Nordisk A/S, insulin detemir + NPH insulin (NCT00474045)
- 2011-11-10Phase 3 first posted: Eli Lilly and Company, LY2605541 + Insulin Glargine (NCT01468987)
- 2011-10-05Results posted on the registry: University of New Mexico, Insulin Detemir + Insulin Glargine (NCT00659165)
- 2011-09-27Results posted on the registry: Novo Nordisk A/S, insulin detemir + insulin glargine (NCT00909480)
- 2011-08-09Results posted on the registry: Arkansas Children's Hospital Research Institute, MDI (split-mix NPH insulin + regular insulin or Lantus + Novolog® [or Humalog®]) (NCT00574405)
- 2011-07-25Results posted on the registry: Novo Nordisk A/S, biphasic insulin aspart + insulin detemir (NCT00184600)
- 2011-07-12Phase 3 first posted: Novo Nordisk A/S, insulin degludec/liraglutide + insulin degludec (NCT01392573)
- 2011-07-06Phase 3 first posted: Novo Nordisk A/S, insulin degludec + insulin aspart (NCT01388361)
- 2011-06-03Phase 3 first posted: Novo Nordisk A/S, insulin degludec/insulin aspart (NCT01365507)
- 2011-06-02Phase 3 first posted: Novo Nordisk A/S, insulin degludec + insulin degludec (NCT01364428)
- 2011-05-13Results posted on the registry: Novo Nordisk A/S, liraglutide + insulin detemir (NCT00856986)
- 2011-05-12Results posted on the registry: Novo Nordisk A/S, insulin detemir + insulin aspart (NCT00447382)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision